Sweden-based medical device company Integrum AB (Nasdaq First North Growth Market: INTEG B) announced on Monday that it has conducted a pre-submission meeting with the US Food and Drug Administration (FDA) to discuss regulatory pathways for the OPRA Implant System in transhumeral (above elbow) amputations.
Following this meeting, Integrum intends to submit a Pre-Market Approval (PMA) application based on existing clinical data.
Having secured PMA for transfemoral (above-knee) amputations in December 2020, Integrum aims to expand regulatory approval to include transhumeral amputations in the US. Following a recent FDA meeting and internal analysis, Integrum believes existing clinical data may suffice for PMA qualification. The company plans to submit the application in the first half of 2024.
Clarity Pharmaceuticals starts registrational Phase III CLARIFY trial
Soligenix's Phase 2a SGX945 clinical trial IND application receives US FDA approval
Johnson & Johnson MedTech acquires Laminar in USD400m deal
Mithra Pharmaceuticals postpones DONESTA NDA filing to allow for additional analyses
GENinCode announces transition of CARDIO inCode-Score FDA submission to De Novo pathway
Carisma Therapeutics' CT-0525 IND application receives US FDA approval
Orexo's OX124 New Drug Application accepted for review by US Food and Drug Administration
GE HealthCare expands Critical Care Suite with FDA-cleared Pneumothorax detection algorithm
NanoVibronix initiates clinical study for UroShield at University of Michigan
Acrivon Therapeutics secures FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Orexo's opioid overdose rescue medication, OX124, gains FDA acceptance for review
SpringWorks Therapeutics' Ogsiveo tablets receive US FDA approval